The latest price target for CVS Health (NYSE:CVS) was reported by Deutsche Bank on December 3, 2024. The analyst firm set a price target for $66.00 expecting CVS to rise to within 12 months (a possible 48.65% upside). 48 analyst firms have reported ratings in the last year.

The latest analyst rating for CVS Health (NYSE:CVS) was provided by Deutsche Bank, and CVS Health upgraded their buy rating.

The last upgrade for CVS Health Corp happened on December 3, 2024 when Deutsche Bank raised their price target to $66. Deutsche Bank previously had a hold for CVS Health Corp.

The last downgrade for CVS Health Corp happened on May 7, 2024 when TD Cowen changed their price target from $99 to $59 for CVS Health Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CVS Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CVS Health was filed on December 3, 2024 so you should expect the next rating to be made available sometime around December 3, 2025.

While ratings are subjective and will change, the latest CVS Health (CVS) rating was a upgraded with a price target of $66.00 to $66.00. The current price CVS Health (CVS) is trading at is $44.40, which is out of the analyst’s predicted range.